

News Release

Your Contact

Media Relations

markus.talanow@emdgroup.com

Phone: +49 6151 72-7144

Investor Relations

investor.relations@emdgroup.com

Phone: +49 6151 72-3321

April 26, 2019

Wolfgang Büchele Re-elected Supervisory Board Chairman of Merck KGaA, Darmstadt, Germany

- **Michael Fletterich confirmed as Vice Chairman**
- **Annual General Meeting approves all agenda items including proposed dividend of € 1.25 per share**
- **Actions of the Executive Board and the Supervisory Board approved by a significant majority**

Frankfurt am Main, Germany April 26, 2019 – The newly appointed Supervisory Board of Merck KGaA, Darmstadt, Germany, today re-elected Wolfgang Büchele (59) as its Chairman at its constitutive meeting directly following the 24th Annual General Meeting. Michael Fletterich (61) was also confirmed as Vice Chairman, representing the employee side. Apart from Büchele, five further shareholder representatives were elected by shareholders at the Annual General Meeting in Frankfurt am Main. Moreover, two shareholder representatives were directly appointed by E. Merck KG, Darmstadt, Germany. The eight employee representative members had already been elected on April 11. The Supervisory Board members are appointed for the period until the end of the Annual General Meeting 2024, which is to resolve on the approval of actions for fiscal 2023.

The new Supervisory Board of Merck KGaA, Darmstadt, Germany, consists of the following members: Dr. Wolfgang Büchele (Chairman), Michael Fletterich (Vice Chairman), Dr. Gabriele Eismann, Edeltraud Glänzer, Jürgen Glaser, Sascha Held, Michael Kleinemeier, Renate Koehler, Anne Lange, Peter Emanuel Merck,

Page 1 of 2



News Release

Dr. Dietmar Oeter, Dr. Christian Raabe, Helene von Roeder, Prof. Dr. Helga Rübsamen-Schaeff, Dr. Daniel Thelen, and Dr. Simon Thelen.

The term of office of the previous Supervisory Board members expired upon conclusion of the 2019 Annual General Meeting.

In addition, the Annual General Meeting approved the actions of the Executive Board and the Supervisory Board of Merck KGaA, Darmstadt, Germany, for fiscal 2018 by a large majority and approved all of the resolutions on the agenda, including the proposed dividend of € 1.25 per share. Merck KGaA, Darmstadt, Germany, is thus maintaining the dividend at a stable level although earnings per share pre (EPS pre), which is decisive for the dividend to be paid, declined in 2018.

Around 1,000 shareholders took part in the Annual General Meeting. When the resolutions were voted on, around 86.5 million shares were represented, corresponding to 66.96 % of the approximately 129.2 million shares issued. The details of the voting results can be found at www.emdgroup.com/agm.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.